諾輝健康(06606.HK)盈喜:預期年度毛利大增313.2%至324.5%
格隆匯1月12日丨諾輝健康-B(06606.HK)公吿,集團截至2022年12月31日止年度的收入總額預期將約人民幣7.505億元至人民幣7.825億元,較截至2021年12月31日止年度增長了252.7%至267.7%。
集團截至2022年12月31日止年度的毛利預期將約乎人民幣6.39億元至人民幣6.56億元,較截至2021年12月31日止年度增長了313.2%至324.5%。
收入總額及毛利增加主要是因為公司的產品(即常衞清及噗噗管)的收入及毛利增加,以及於2022年1月新產品幽幽管上市。公司截至2022年12月31日止年度的毛利率預期將介於81.6%至87.4%,較截至2021年12月31日止年度的約72.7%呈上升趨勢。公司的整體毛利率提高主要是因為常衞清及噗噗管的毛利率均有所增加,以及幽幽管的毛利率頗為可觀。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.